Foresite Capital Management Iv, LLC Cyma Bay Therapeutics, Inc. Transaction History

Foresite Capital Management Iv, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$3.32 - $7.24 $3.51 Million - $7.65 Million	-1,056,799 Reduced 37.16%	1,787,094 $12.9 Million
Q2 2020 Aug 13, 2020	BUY	$1.41 - $4.25 $4.01 Million - $12.1 Million	2,843,893 New	2,843,893 $9.93 Million
Q1 2020 May 14, 2020	SELL	$1.25 - $2.02 $2.89 Million - $4.68 Million	-2,315,016 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.33 - $5.93 $338,814 - $1.51 Million	254,748 Added 12.36%	2,315,016 $4.54 Million
Q3 2019 Nov 13, 2019	SELL	$5.12 - $7.21 $2.62 Million - $3.68 Million	-510,990 Reduced 19.87%	2,060,268 $10.5 Million
Q2 2019 Aug 13, 2019	SELL	$6.05 - $13.66 $363,000 - $819,600	-60,000 Reduced 2.28%	2,571,258 $18.4 Million
Q4 2018 Feb 13, 2019	BUY	$6.54 - $11.74 $3.98 Million - $7.14 Million	607,889 Added 30.04%	2,631,258 $20.7 Million
Q2 2018 Aug 14, 2018	SELL	$10.66 - $14.38 $943,410 - $1.27 Million	-88,500 Reduced 4.19%	2,023,369 $27.2 Million
Q1 2018 May 15, 2018	SELL	$9.0 - $15.16 $1.28 Million - $2.16 Million	-142,633 Reduced 6.33%	2,111,869 $27.4 Million
Q4 2017 Feb 13, 2018	BUY	$7.67 - $9.31 $17.3 Million - $21 Million	2,254,502	2,254,502 $20.7 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Foresite Capital Management Iv, LLC, based on Form 13F filings with the SEC.

Stay updated on Foresite Capital Management Iv, LLC with notifications on news.